Literature DB >> 16773362

[Pneumonia - pathogen-based or constellation-based therapy?].

A Kuhnke1, T Welte, N Suttorp.   

Abstract

Community-acquired pneumonia is one of the most frequent infectious diseases with high morbidity and mortality. Early and sufficient antibiotic treatment is crucial for the prognosis of the patient. The underlying pathogens are mostly unknown at the onset of symptoms. The choice of antibiotic treatment depends on the suspected pathogens, derived from the typical germs and the typical resistances in a certain area. In addition, individual risk factors, such as age, severity of the diseases, comorbidities, and previous antibiotic treatment have a major impact on the probability of dying for an individual patient. These factors must be considered at the beginning of any treatment. Pathogen-based treatment has to be switched to constellation-based treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773362     DOI: 10.1007/s00108-006-1623-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia.

Authors:  Beatriz Rosón; Nuria Fernández-Sabé; Jordi Carratalà; Ricard Verdaguer; Jordi Dorca; Frederic Manresa; Francesc Gudiol
Journal:  Clin Infect Dis       Date:  2003-12-18       Impact factor: 9.079

3.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Authors:  José A Martínez; Juan P Horcajada; Manuel Almela; Francesc Marco; Alex Soriano; Elisa García; Maria Angeles Marco; Antoni Torres; Josep Mensa
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

4.  Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.

Authors:  Tobias Welte; Wolfgang Petermann; Dirk Schürmann; Torsten Thomas Bauer; Peter Reimnitz
Journal:  Clin Infect Dis       Date:  2005-11-10       Impact factor: 9.079

5.  Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity.

Authors:  M Ruiz; S Ewig; M A Marcos; J A Martinez; F Arancibia; J Mensa; A Torres
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

6.  Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.

Authors:  Graham D Mills; Michael R Oehley; Bruce Arrol
Journal:  BMJ       Date:  2005-01-31

7.  Quality of care, process, and outcomes in elderly patients with pneumonia.

Authors:  T P Meehan; M J Fine; H M Krumholz; J D Scinto; D H Galusha; J T Mockalis; G F Weber; M K Petrillo; P M Houck; J M Fine
Journal:  JAMA       Date:  1997-12-17       Impact factor: 56.272

Review 8.  [New therapeutic strategies for community acquired pneumonia].

Authors:  T Welte; R Marre; N Suttorp
Journal:  Internist (Berl)       Date:  2005-12       Impact factor: 0.743

9.  Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease.

Authors:  Jürgen H Helbig; Søren A Uldum; Sverker Bernander; Paul Christian Lück; Günther Wewalka; Bill Abraham; Valeria Gaia; Timothy G Harrison
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

10.  Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.

Authors:  R Finch; D Schürmann; O Collins; R Kubin; J McGivern; H Bobbaers; J L Izquierdo; P Nikolaides; F Ogundare; R Raz; P Zuck; G Hoeffken
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.